Suyu Liu, PhD

Peer-Reviewed Articles

1. Corn PG, Yu G, Fan Y, Zhang M, Troncoso P, Surasi DS, Liu S, Ajani JA, Logothetis CJ, Wang G, Panaretakis T, Lin SH. Spatial immune profiling of bone-metastatic castration-resistant prostate cancer reveals radium-223 immunomodulates the bone-tumor microenvironment. Prostate Cancer Prostatic Dis, 2025. e-Pub 2025. PMID: 41454189.
2. Vadivalagan C, Zhang J, Dai J, Liu S, Singal AG, Bass K, Parikh ND, Lubman DM. Integrative Analysis of Fucosylated Tetra Glycoforms in Hepatocellular Carcinoma: A NanoLC-PRM-MS/MS and Machine Learning Approach. J Proteome Res 24(12):6079-6090, 2025. e-Pub 2025. PMID: 41212027.
3. Zhang J, Wang T, Qu Y, Yan F, Liu S, Lin R. Bayesian Integrated Learning of Longitudinal Dose-Response Relationships via Decentralized Clinical Trials. Stat Med 44(28-30):e70338, 2025. e-Pub 2025. PMID: 41339943.
4. Zhu, Y, Solis Soto, LM, Pant, S, Vega, EA, Vinuela, E, Bozorgui, B, Vauthey, JN, Aguayo, G, Wang, Z, Lu, W, Chen, X, Mino, B, Kakarala, L, Dai, J, Liu, S, Wani, K, Lazar, A, Carapeto, F, Lee, S, Wistuba, II, Korkut, A, Javle, M, Kwong, L. Population-Specific Immunogenomic Alterations in Gallbladder Cancer and Prognostic Significance. Modern Pathology 38(11), 2025. e-Pub 2025. PMID: 40541865.
5. Han Y, Qiu Y, Zhao Y, Wan I, Li L, Liu S, Zang Y. Great Wall: A Generalized Dose Optimization Design for Drug Combination Trials Maximizing Survival Benefit. Pharm Stat 24(6):e70049, 2025. e-Pub 2025. PMID: 41221813.
6. Wang S, Yuan Y, Liu S. Randomized optimal selection design for dose optimization. Biometrics 81(4), 2025. e-Pub 2025. PMID: 41059993.
7. Tang C, Sherry AD, Seo A, Hara K, Choi H, Liu S, Sun X, Montoya A, Ludmir EB, Shah AY, Jonasch E, Zurita AJ, Kovitz C, Alhalabi O, Goswami S, Hahn AW, Campbell MT, Hernandez A, Nead KT, Van Loo P, Su S, Battey CJ, LaBella ML, Ratzel S, Acevedo A, Genovese G, Sircar K, Karam JA, Tannir NM, Msaouel P. Metastasis-directed radiotherapy without systemic therapy for oligometastatic clear-cell renal-cell carcinoma: primary efficacy analysis of a single-arm, single-centre, phase 2 trial. Lancet Oncol 26(10):1289-1299, 2025. e-Pub 2025. PMID: 40915303.
8. Sherry AD, Siddiqui BA, Haymaker C, Fellman BM, Medina-Rosales MN, Bathala TK, Wang S, Liu S, Seo A, Hara K, Lu H, Troncoso P, Chun SG, Ha CS, Mayo LL, Mok H, Park RJ, Chapin BF, Phillips RM, Deek MP, Kovitz CA, Aparicio A, Zurita AJ, Pilie PG, Cohen L, Choi SL, Reuben A, Tran PT, Corn PG, Subudhi SK, Tang C. Continuous Androgen Deprivation Therapy with or Without Metastasis-directed Therapy for Oligometastatic Prostate Cancer: The Multicenter Phase 2 Randomized EXTEND Trial. Eur Urol 88(5):496-509, 2025. e-Pub 2025. PMID: 40750497.
9. Cabanillas, ME, Busaidy, NL, Gunn, GB, Iyer, PC, Ferrarotto, R, Gule-Monroe, MK, Maniakas, A, Williams, MD, Liu, S, Fellman, B, Spiotto, MT, Hamidi, S, Akhave, NS, Lee, A, Wang, RJ, De Sousa, LG, Marczyk, VR, Zafereo, M, Dadu, R. Adjuvant Pembrolizumab after Upfront Multimodal Therapy for Stage IVB Anaplastic Thyroid Cancer. Thyroid 35(7):763-770, 2025. e-Pub 2025. PMID: 40609521.
10. Qin, L, Moreno Rueda, LY, Ray, U, Mahmud, I, Tan, L, Lorenzi, PL, Liu, S, Lin, Y, Mery, D, Zhan, F, Shaughnessy, JD, Yi, Q, Acevedo Calado, MJ, Wang, H, Manasanch, EE, Lee, HC, Patel, K, Kuiatse, I, Symer, DE, Orlowski, R. Targeting caseinolytic mitochondrial matrix peptidase, a novel contributor to the pathobiology of high-risk multiple myeloma. Blood 145(22):2614-2629, 2025. e-Pub 2025. PMID: 39912779.
11. Morris VK, Liu S, Lin K, Zhu H, Prasad S, Mahvash A, Bhosale P, Sun B, Parra ER, Wistuba I, Peddireddy A, Yao J, Mendoza-Perez J, Knafl M, Woodman SE, Eng C, Halperin D. Phase II Trial of Atezolizumab and Bevacizumab for Treatment of HPV-Positive Unresectable or Metastatic Squamous Cell Carcinoma of the Anal Canal. Clin Cancer Res 31(9):1657-1666, 2025. e-Pub 2025. PMID: 40019482.
12. Jiang X, Rudqvist NP, Jiang B, Ye S, He S, Liang Q, Dou J, Williams MD, Dunn JD, Johnson JM, Akagi K, Xiao W, Liang S, Elayavalli S, Sun B, Parra ER, Ferrarotto R, Garden AS, Fuller CD, Reddy J, Gross ND, Lango MN, Leung CH, Liu S, Liu DD, Li M, Lee JJ, Curran MA, Phan J, Chen K, Gillison ML. Depletion of effector regulatory T cells associates with major response to induction dual immune checkpoint blockade. Cancer Discov 15(8):1569-1592, 2025. e-Pub 2025. PMID: 40249124.
13. Tian F, Lin R, Liu S, Yuan Y. Sample-size determination for decentralized clinical trials. Int J Epidemiol 54(3), 2025. e-Pub 2025. PMID: 40393699.
14. Maher, MH, Treekitkarnmongkol, W, Ghatak, S, Dai, J, Liu, S, Nguyen, T, Duose, D, Kim, M, Hu, T, Hurd, MW, Paris, PL, Kirkwood, K, Maitra, A, Luthra, R, Sen, S, Roy Chowdhuri, S. An integrated multi-omics biomarker approach using molecular profiling and microRNAs for evaluation of pancreatic cyst fluid. Cancer Cytopathology 133(4), 2025. PMID: 40106268.
15. Reddy JP, Sherry AD, Fellman B, Liu S, Bathala T, Haymaker C, Cohen L, Smith BD, Ramirez D, Shaitelman SF, Chun SG, Medina-Rosales M, Teshome M, Brewster A, Barcenas CH, Reuben A, Ghia AJ, Ludmir EB, Weed D, Shah SJ, Mitchell MP, Woodward WA, Gomez DR, Tang C. Adding Metastasis-Directed Therapy to Standard-of-Care Systemic Therapy for Oligometastatic Breast Cancer (EXTEND): a Multicenter, Randomized Phase II Trial. Int J Radiat Oncol Biol Phys 121(4):885-893, 2025. e-Pub 2025. PMID: 39486645.
16. Guo, B, Liu, S. A Phase I Dose-Finding Design Incorporating Intra-Patient Dose Escalation. Pharmaceutical statistics 24(2), 2025. PMID: 39722206.
17. Wotman, MT, Xiao, W, Du, R, Jiang, B, Akagi, K, Liu, S, Gillison, M. Development and Validation of an Assay to Quantify Plasma Circulating Tumor Human Papillomavirus DNA for 13 High-Risk Types that Cause 98% of HPV-Positive Cancers. Head and Neck Pathology 19(25), 2025. PMID: 39998590.
18. Wang L, Zhang S, Wei L, Zhu Y, Fareed N, Cheng L, Carson W, Owen D, Zang Y, Liu S, Shendre A, Liu X, Li L. DrugCombo: an informatics bridge for anticancer drug combination Phase I trial design. Database (Oxford) 2025, 2025. e-Pub 2025. PMID: 40996717.
19. Lu M, Yuan Y, Liu S. A Bayesian pharmacokinetics integrated phase I-II design to optimize dose-schedule regimes. Biostatistics 26(1), 2025. e-Pub 2024. PMID: 39275895.
20. Ludmir EB, Sherry AD, Fellman BM, Liu S, Bathala T, Haymaker C, Medina-Rosales MN, Reuben A, Holliday EB, Smith GL, Noticewala SS, Nicholas S, Price TR, Martin-Paulpeter RM, Perles LA, Lee SS, Lee MS, Smaglo BG, Huey RW, Willis J, Zhao D, Cohen L, Taniguchi CM, Koay EJ, Katz MHG, Wolff RA, Das P, Pant S, Koong AC, Tang C. Addition of Metastasis-Directed Therapy to Systemic Therapy for Oligometastatic Pancreatic Ductal Adenocarcinoma (EXTEND): A Multicenter, Randomized Phase II Trial. J Clin Oncol 42(32):3795-3805, 2024. e-Pub 2024. PMID: 39102622.
21. Cabanillas ME, Dadu R, Ferrarotto R, Gule-Monroe M, Liu S, Fellman B, Williams MD, Zafereo M, Wang JR, Lu C, Ning M, McKinley BA, Woodman SE, Duose D, Gunn GB, Busaidy NL. Anti-Programmed Death Ligand 1 Plus Targeted Therapy in Anaplastic Thyroid Carcinoma: A Nonrandomized Clinical Trial. JAMA Oncol 10(12):1672-1680, 2024. e-Pub 2024. PMID: 39446377.
22. Jin, IH, Liu, F, Park, J, Eugenio, E, Liu, S. Bayesian hierarchical spatial model for small-area estimation with non-ignorable nonresponses and its application to the NHANES dental caries data. Journal of the Korean Statistical Society 53(4):949-969, 2024. e-Pub 2024.
23. Yuan Y, Zhou H, Liu S. Statistical and practical considerations in planning and conduct of dose-optimization trials. Clin Trials 21(3):273-286, 2024. e-Pub 2024. PMID: 38243399.
24. Shi C, De B, Tran Cao HS, Liu S, Florez MA, Kouzy R, Grippin AJ, Katz MHG, Tzeng CD, Ikoma N, Kim MP, Lee S, Willis J, Noticewala SS, Minsky BD, Smith GL, Holliday EB, Taniguchi CM, Koong AC, Das P, Ludmir EB, Koay EJ. Escalated-dose radiotherapy for unresected locally advanced pancreatic cancer: Patterns of care and survival in the United States. Cancer Med 13(12):e7434, 2024. PMID: 38923407.
25. Hornstein NJ, Zeineddine MA, Gunes BB, Pellatt AJ, Knafl M, Zhu H, Willett AF, Yousef A, Liu S, Sun R, Futreal A, Woodman SE, Taggart MW, Overman MJ, Halperin DM, Raghav KP, Shen JP. Efficacy and Safety of Atezolizumab and Bevacizumab in Appendiceal Adenocarcinoma. Cancer Res Commun 4(5):1363-1368, 2024. e-Pub 2024. PMID: 38709066.
26. Treekitkarnmongkol W, Solis LM, Sankaran D, Gagea M, Singh PK, Mistry R, Nguyen T, Kai K, Liu J, Sasai K, Jitsumori Y, Liu J, Nagao N, Stossi F, Mancini MA, Wistuba II, Thompson AM, Lee JM, Cadiñanos J, Wong KK, Abbott CM, Sahin AA, Liu S, Katayama H, Sen S. eEF1A2 promotes PTEN-GSK3β-SCF complex-dependent degradation of Aurora kinase A and is inactivated in breast cancer. Sci Signal 17(826):eadh4475, 2024. e-Pub 2024. PMID: 38442201.
27. Treekitkarnmongkol W, Dai J, Liu S, Sankaran D, Nguyen T, Balasenthil S, Hurd MW, Chen M, Katayama H, Roy-Chowdhuri S, Calin GA, Brand RE, Lampe PD, Hu TY, Maitra A, Koay EJ, Killary AM, Sen S. Blood-Based microRNA Biomarker Signature of Early-Stage Pancreatic Ductal Adenocarcinoma With Lead-Time Trajectory in Prediagnostic Samples. Gastro Hep Adv 3(8):1098-1115, 2024. e-Pub 2024. PMID: 39529638.
28. Balasenthil S, Liu S, Dai J, Bamlet WR, Petersen G, Chari ST, Maitra A, Chen N, Sen S, McNeill Killary A. Blood-based Migration Signature Biomarker Panel Discriminates Early Stage New Onset Diabetes related Pancreatic Ductal Adenocarcinoma from Type 2 Diabetes. Clin Chim Acta 551:117567, 2023. e-Pub 2023. PMID: 37774897.
29. Tang C, Sherry AD, Haymaker C, Bathala T, Liu S, Fellman B, Cohen L, Aparicio A, Zurita AJ, Reuben A, Marmonti E, Chun SG, Reddy JP, Ghia A, McGuire S, Efstathiou E, Wang J, Wang J, Pilie P, Kovitz C, Du W, Simiele SJ, Kumar R, Borghero Y, Shi Z, Chapin B, Gomez D, Wistuba I, Corn PG. Addition of Metastasis-Directed Therapy to Intermittent Hormone Therapy for Oligometastatic Prostate Cancer: The EXTEND Phase 2 Randomized Clinical Trial. JAMA Oncol 9(6):825-834, 2023. e-Pub 2023. PMID: 37022702.
30. Cohen EN, Jayachandran G, Gao H, Peabody P, McBride HB, Alvarez FD, Bravo PL, Qiao W, Liu S, Yao L, Lin SH, Reuben JM. Gene expression profiling of circulating tumor cells captured by MicroCavity Array is superior to enumeration in demonstrating therapy response in patients with newly diagnosed advanced and locally advanced non-small cell lung cancer. Transl Lung Cancer Res 12(1):109-126, 2023. e-Pub 2023. PMID: 36762061.
31. Mechref Y, Peng W, Gautam S, Ahmadi P, Lin Y, Zhu J, Zhang J, Liu S, Singal AG, Parikh ND, Lubman DM. Mass spectrometry based biomarkers for early detection of HCC using a glycoproteomic approach. Adv Cancer Res 157:23-56, 2023. e-Pub 2023. PMID: 36725111.
32. Sherry AD, Bathala TK, Liu S, Fellman BM, Chun SG, Jasani N, Guadagnolo BA, Jhingran A, Reddy JP, Corn PG, Shah AY, Kaiser KW, Ghia AJ, Gomez DR, Tang C. Definitive Local Consolidative Therapy for Oligometastatic Solid Tumors: Results from the Lead-in Phase of the Randomized Basket Trial EXTEND. Int J Radiat Oncol Biol Phys S0360-3016(22):00475-8, 2022. e-Pub 2022. PMID: 35691448.
33. Le UQ, Chen N, Balasenthil S, Lurie E, Yang F, Liu S, Rubin L, Solis Soto LM, Raso MG, Batra H, Sahin AA, Wistuba II, Killary AM. Tumor suppressor DEAR1 regulates mammary epithelial cell fate and predicts early onset and metastasis in triple negative breast cancer. Sci Rep 12(1):19504, 2022. e-Pub 2022. PMID: 36376460.
34. Qiao W, Young E, Feng C, Liu S, Jin J, Noor L, Rojas Hernandez CM, Borthakur G, Gorlova O, Afshar-Kharghan V. Association between abnormal lipid profile and inflammation and progression of myelodysplastic syndrome to acute leukemia. Exp Hematol Oncol 11(1):58, 2022. e-Pub 2022. PMID: 36114519.
35. Lin Y, Zhu J, Zhang J, Dai J, Liu S, Arroyo A, Rose M, Singal AG, Parikh ND, Lubman DM. Glycopeptides with Sialyl Lewis Antigen in Serum Haptoglobin as Candidate Biomarkers for Nonalcoholic Steatohepatitis Hepatocellular Carcinoma Using a Higher-Energy Collision-Induced Dissociation Parallel Reaction Monitoring-Mass Spectrometry Method. ACS Omega 7(26):22850-22860, 2022. e-Pub 2022. PMID: 35811936.
36. Lu M, Liu S, Yuan Y. Why there are so many contradicted or exaggerated findings in highly-cited clinical research?. Contemp Clin Trials 118:106782, 2022. e-Pub 2022. PMID: 35525531.
37. Halperin DM, Liu S, Dasari A, Fogelman D, Bhosale P, Mahvash A, Estrella JS, Rubin L, Morani AC, Knafl M, Overeem TA, Fu SC, Solis LM, Parra Cuentas E, Verma A, Chen HL, Gite S, Subashchandrabose P, Dervin S, Schulze K, Darbonne WC, Yun C, Wistuba II, Futreal PA, Woodman SE, Yao JC. Assessment of Clinical Response Following Atezolizumab and Bevacizumab Treatment in Patients With Neuroendocrine Tumors: A Nonrandomized Clinical Trial. JAMA Oncol 8(7):e220212, 2022. e-Pub 2022. PMID: 35389428.
38. Park Y, Liu S. A randomized group sequential enrichment design for immunotherapy and targeted therapy. Contemp Clin Trials 116:106742, 2022. e-Pub 2022. PMID: 35405335.
39. Park Y, Liu S, Thall PF, Yuan Y. Bayesian group sequential enrichment designs based on adaptive regression of response and survival time on baseline biomarkers. Biometrics 78(1):60-71, 2022. e-Pub 2022. PMID: 33438761.
40. Gjyshi O, Lin SH, Pezzi TA, Ning MS, Ma J, Liu S, Rusthoven CG. Care Patterns for Stereotactic Radiosurgery in Small Cell Lung Cancer Brain Metastases. Clin Lung Cancer 23(2):185-190, 2022. e-Pub 2022. PMID: 34419375.
41. Dev R, Zhong LL, Zarifa A, Albittar AA, Rubin L, Liu S, Yap TA, Dalal S, Hui D, Karp DD, Tsimberidou AM, Piha-Paul SA, Ahnert JR, Fu S, Meric-Bernstam F, Naing A. Supportive care for the prevention of nausea, vomiting and anorexia in a phase 1B study of selinexor in advanced cancer patients: an exploratory study. Invest New Drugs 40(1):124-133, 2022. e-Pub 2022. PMID: 34559346.
42. Douglas JE, Liu S, Ma J, Wolff RA, Pant S, Maitra A, Tamm EP, Bhosale P, Katz MHG, Varadhachary GR, Koay EJ. PIONEER-Panc: a platform trial for phase II randomized investigations of new and emerging therapies for localized pancreatic cancer. BMC Cancer 22(1):14, 2022. e-Pub 2022. PMID: 34980020.
43. Raghav K, Liu S, Overman MJ, Willett AF, Knafl M, Fu SC, Malpica A, Prasad S, Royal RE, Scally CP, Mansfield PF, Wistuba II, Futreal AP, Maru DM, Solis Soto LM, Parra Cuentas ER, Chen H, Villalobos P, Verma A, Mahvash A, Hwu P, Cortazar P, McKenna E, Yun C, Dervin S, Schulze K, Darbonne WC, Morani AC, Kopetz S, Fournier KF, Woodman SE, Yao JC, Varadhachary GR, Halperin DM. Efficacy, Safety and Biomarker Analysis of Combined PD-L1 (Atezolizumab) and VEGF (Bevacizumab) Blockade in Advanced Malignant Peritoneal Mesothelioma. Cancer Discov 11(11):2738-2747, 2021. e-Pub 2021. PMID: 34261675.
44. Guo, Garrett‐Mayer, Liu. A Bayesian phase I/II design for cancer clinical trials combining an immunotherapeutic agent with a chemotherapeutic agent. Journal of the Royal Statistical Society: Series C (Applied Statistics) 70(5):1210-1229, 2021. e-Pub 2021.
45. Gutierrez Reyes CD, Huang Y, Atashi M, Zhang J, Zhu J, Liu S, Parikh ND, Singal AG, Dai J, Lubman DM, Mechref Y. PRM-MS Quantitative Analysis of Isomeric N-Glycopeptides Derived from Human Serum Haptoglobin of Patients with Cirrhosis and Hepatocellular Carcinoma. Metabolites 11(8), 2021. e-Pub 2021. PMID: 34436504.
46. Raghav K, Liu S, Overman M, Morani A, Willette A, Fournier K, Varadhachary G. Clinical Efficacy of Immune Checkpoint Inhibitors in Patients With Advanced Malignant Peritoneal Mesothelioma. JAMA Netw Open 4(8):e2119934, 2021. e-Pub 2021. PMID: 34357397.
47. Dittmar RL, Liu S, Tai MC, Rajapakshe K, Huang Y, Longton G, DeCapite C, Hurd MW, Paris PL, Kirkwood KS, Coarfa C, Maitra A, Brand RE, Killary AM, Sen S. Plasma miRNA Biomarkers in Limited Volume Samples for Detection of Early-stage Pancreatic Cancer. Cancer Prev Res (Phila) 14(7):729-740, 2021. e-Pub 2021. PMID: 33893071.
48. Park Y, Yuan Y, Ning J, Liu S, Feng Z. Hybrid design evaluating new biomarkers when there is an existing screening test. Stat Med 40(8):2037-2054, 2021. e-Pub 2021. PMID: 33540472.
49. Park M, Liu S, Yap TA, Yuan Y. Evaluation of Deviation From Planned Cohort Size and Operating Characteristics of Phase 1 Trials. JAMA Netw Open 4(2):e2037563, 2021. e-Pub 2021. PMID: 33595664.
50. Park Y, Liu S. On the coherence of model-based dose-finding designs for drug combination trials. PLoS One 30(15), 2020. e-Pub 2020. PMID: 33253260.
51. Cohen EN, Jayachandran G, Gao H, Qiao W, Liu S, He J, Qiao Y, Yao L, Lin SH, Reuben JM. Enumeration and molecular characterization of circulating tumor cells enriched by microcavity array from stage III non-small cell lung cancer patients. Transl Lung Cancer Res 9(5):1974-1985, 2020. e-Pub 2020. PMID: 33209617.
52. Zhu J, Huang J, Zhang J, Chen Z, Lin Y, Grigorean G, Li L, Liu S, Singal AG, Parikh ND, Lubman DM. Glycopeptide Biomarkers in Serum Haptoglobin for Hepatocellular Carcinoma Detection in Patients with Nonalcoholic Steatohepatitis. J Proteome Res 19(8):3452-3466, 2020. e-Pub 2020. PMID: 32412768.
53. Pezzi TA, Fang P, Gjyshi O, Feng L, Liu S, Komaki R, Lin SH. Rates of Overall Survival and Intracranial Control in the Magnetic Resonance Imaging Era for Patients With Limited-Stage Small Cell Lung Cancer With and Without Prophylactic Cranial Irradiation. JAMA Netw Open 3(4):e201929, 2020. e-Pub 2020. PMID: 32236532.
54. Guo B, Liu S. An optimal Bayesian predictive probability design for phase II clinical trials with simple and complicated endpoints. Biom J 62(2):339-349, 2020. e-Pub 2020. PMID: 31402481.
55. Yan F, Pan H, Zhang L, Liu S, Yuan Y. BOIN: An R package for designing single-agent and drug-combination dose-finding trials using Bayesian optimal interval designs. Journal of Statistical Software 94(13):1-32, 2020. e-Pub 2020.
56. Park Y, Liu S. On the coherence of model-based dose-finding designs for drug combination trials. PLoS One 15(11):e0242561, 2020. e-Pub 2020. PMID: 33253260.
57. Shen W, Liu S, Chen Y, Ning J. Regression analysis of longitudinal data with outcome-dependent sampling and informative censoring. Scand Stat Theory Appl 46(3):831-847, 2019. e-Pub 2019. PMID: 32066989.
58. Liang J, Zhu J, Wang M, Singal AG, Odewole M, Kagan S, Renteria V, Liu S, Parikh ND, Lubman DM. Evaluation of AGP Fucosylation as a Marker for Hepatocellular Carcinoma of Three Different Etiologies. Sci Rep 9(1):11580, 2019. e-Pub 2019. PMID: 31399619.
59. Guo B, Park Y, Liu S. A Utility-based Bayesian phase I–II design for immunotherapy trials with progression-free survival endpoint. Journal of the Royal Statistical Society (series C) 68(2):411-425, 2019. e-Pub 2019.
60. Manzano JG, Park A, Lin H, Liu S, Halm J. Demonstrating value: association of cost and quality outcomes with implementation of a value-driven oncology-hospitalist inpatient collaboration for patients with lung cancer. BMJ Open Qual 8(1):e000381, 2019. e-Pub 2019. PMID: 30997414.
61. Pundole X, Murphy WA, Ebede CC, Karim E, Manocha S, Don-Pedro D, Rondon G, Leung CH, Liu S, Du XL, Champlin RE, Lu H. Fracture risk prediction using FRAX in patients following hematopoietic stem cell transplantation. Arch Osteoporos 13(1):38, 2018. e-Pub 2018. PMID: 29619576.
62. Pan H, Liu S, Miao D, Yuan Y. Sample size determination for mediation analysis of longitudinal data. BMC Medical Research Methodology 18(1):32, 2018. e-Pub 2018. PMID: 29580203.
63. Zhang X, Sun M, Liu S, Leung CH, Pang L, Popat UR, Champlin R, Holmes HM, Valero V, Dinney CP, Tripathy D, Edwards BJ. Risk factors for falls in older patients with cancer. BMJ Support Palliat Care 8(1):34-37, 2018. e-Pub 2018. PMID: 28860112.
64. Guo B, Liu S. Optimal benchmark for evaluating drug-combination dose-finding clinical trials. Statistics in Bio-sciences 10:184-201, 2018. e-Pub 2018.
65. Liu S, Guo B, Yuan Y. A Bayesian phase I-II trial design for immunotherapy. Journal of the American Statistical Association 113(523):1016-1027, 2018. e-Pub 2018. PMID: 31741544.
66. Balasenthil S, Huang Y, Liu S, Marsh T, Chen J, Stass SA, KuKuruga D, Brand R, Chen N, Frazier ML, Jack Lee J, Srivastava S, Sen S, McNeill Killary A. A Plasma Biomarker Panel to Identify Surgically Resectable Early-Stage Pancreatic Cancer. J Natl Cancer Inst 109(8), 2017. e-Pub 2017. PMID: 28376184.
67. Zang Y, Liu S, Yuan Y. Optimal marker-strategy clinical trial design to detect predictive markers for targeted therapy. Biostatistics 17(3):549-560, 2016. e-Pub 2016. PMID: 26951724.
68. Gu X, Chen N, Wei C, Liu S, Papadimitrakopoulou VA, Herbst RS, and Lee JJ. Bayesian Two-stage Biomarker-based Adaptive Design for Targeted Therapy Development. Statistics in Bioscience 8(1):99-128, 2016. e-Pub 2016. PMID: 27617040.
69. Liu S, Johnson VE. A robust Bayesian dose-finding design for phase I/II clinical trials. Biostatistics 17(2):249-63, 2016. e-Pub 2016. PMID: 26486139.
70. Zang Y, Liu S, Yuan Y. Optimal Marker-Adaptive Designs for Targeted Therapy Based on Imperfectly Measured Biomarkers. Journal of the Royal Statistical Society (series C) 64(4):635-650, 2015. e-Pub 2015.
71. Liu S, Pan H, Xia J, Huang Q, Yuan Y. Bridging Continual Reassessment Method for Phase I Clinical Trials in Different Ethnic Populations. Stat Med 34(10):1681-94, 2015. e-Pub 2015. PMID: 25626429.
72. Liu S, Yuan Y. Bayesian Decision-optimal Interval Designs for Phase I Clinical Trials. Journal of the Royal Statistics Society (series C) 64(3):507-523, 2015. e-Pub 2015.
73. Cai C, Liu S, Yuan Y. A Bayesian design for phase II clinical trials with delayed responses based on multiple imputation. Stat Med 33(23):4017-28, 2014. e-Pub 2014. PMID: 24817556.
74. Liu S, Yuan Y, Castillo R, Guerrero T, Johnson VE. Evaluation of image registration spatial accuracy using a Bayesian hierarchical model. Biometrics 70(2):366-77, 2014. e-Pub 2014. PMID: 24575781.
75. Jin IH, Liu S, Thall PF, Yuan Y. Using data augmentation to facilitate conduct of phase I/II clinical trials with delayed outcomes. J Am Stat Assoc 109(506):525-536, 2014. e-Pub 2014. PMID: 25382884.
76. Blumenschein GR, Saintigny P, Liu S, Kim ES, Tsao AS, Herbst RS, Alden C, Lee JJ, Tang X, Stewart DJ, Kies MS, Fossella FV, Tran HT, Mao L, Hicks ME, Erasmus J, Gupta S, Girard L, Peyton M, Diao L, Wang J, Davis SE, Minna JD, Wistuba I, Hong WK, Heymach JV, Lippman SM. Comprehensive biomarker analysis and final efficacy results of sorafenib in the BATTLE trial. Clin Cancer Res 19(24):6967-75, 2013. e-Pub 2013. PMID: 24166906.
77. Liu S, Yin G, Yuan Y. Bayesian Data Augmentation Dose Finding With Continual Reassessment Method And Delayed Toxicity. Ann Appl Stat 7(4):1837-2457, 2013. e-Pub 2013. PMID: 24707327.
78. Ahn J, Liu S, Wang W, Yuan Y. Bayesian latent-class mixed-effect hybrid models for dyadic longitudinal data with non-ignorable dropouts. Biometrics 69(4):914-24, 2013. e-Pub 2013. PMID: 24328715.
79. Liu S, Cai C, Ning J. Up-and-down designs for phase I clinical trials. Contemp Clin Trials 36(1):218-27, 2013. e-Pub 2013. PMID: 23856381.
80. Liu S, Ning J. A Bayesian Dose-finding Design for Drug Combination Trials with Delayed Toxicities. Bayesian Anal 8(3):703-722, 2013. e-Pub 2013. PMID: 27924182.
81. Tsao AS, Liu S, Lee JJ, Alden CM, Blumenschein GR, Herbst R, Davis SE, Kim E, Lippman S, Heymach J, Tran H, Tang X, Wistuba I, Hong WK. Clinical and biomarker outcomes of the phase II vandetanib study from the BATTLE trial. J Thorac Oncol 8(5):658-61, 2013. e-Pub 2013. PMID: 23584298.
82. Liu S, Ning J. Bayesian Dose-finding Design for Drug Combination Trials with Delayed Toxicities. Bayesian Analysis 8:703-722, 2013. e-Pub 2013. PMID: 27924182.
83. Tsao AS, Liu S, Lee JJ, Alden C, Blumenschein G, Herbst R, Davis SE, Kim E, Lippman S, Stewart D, Tang XM, Wistuba I, Hong WK. Clinical outcomes and biomarker profiles of elderly pretreated NSCLC patients from the BATTLE trial. J Thorac Oncol 7(11):1645-52, 2012. e-Pub 2012. PMID: 23059780.
84. Ihle NT, Byers LA, Kim ES, Saintigny P, Lee JJ, Blumenschein GR, Tsao A, Liu S, Larsen JE, Wang J, Diao L, Coombes KR, Chen L, Zhang S, Abdelmelek MF, Tang X, Papadimitrakopoulou V, Minna JD, Lippman SM, Hong WK, Herbst RS, Wistuba II, Heymach JV, Powis G. Effect of KRAS oncogene substitutions on protein behavior: implications for signaling and clinical outcome. J Natl Cancer Inst 104(3):228-39, 2012. e-Pub 2012. PMID: 22247021.
85. Tsao AS, Liu S, Fujimoto J, Wistuba II, Lee JJ, Marom EM, Charnsangavej C, Fossella FV, Tran HT, Blumenschein GR, Papadimitrakopoulou V, Kies MS, Hong WK, Stewart DJ. Phase II trials of imatinib mesylate and docetaxel in patients with metastatic non-small cell lung cancer and head and neck squamous cell carcinoma. J Thorac Oncol 6(12):2104-11, 2011. e-Pub 2011. PMID: 21892101.
86. Sabichi AL, Lee JJ, Grossman HB, Liu S, Richmond E, Czerniak BA, De la Cerda J, Eagle C, Viner JL, Palmer JL, Lerner SP. A randomized controlled trial of celecoxib to prevent recurrence of nonmuscle-invasive bladder cancer. Cancer Prev Res (Phila) 4(10):1580-9, 2011. e-Pub 2011. PMID: 21881030.
87. Momoh AO, Yu P, Skoracki RJ, Liu S, Feng L, Hanasono MM. A prospective cohort study of fibula free flap donor-site morbidity in 157 consecutive patients. Plast Reconstr Surg 128(3):714-20, 2011. e-Pub 2011. PMID: 21572380.
88. Kim ES, Herbst RS, Wistuba II, Lee JJ, Blumenschein GR, Tsao A, Stewart DJ, Hicks ME, Erasmus J, Gupta S, Alden CM, Liu S, Tang X, Khuri FR, Tran HT, Johnson BE, Heymach JV, Mao L, Fossella F, Kies MS, Papadimitrakopoulou V, Davis SE, Lippman SM, Hong WK. The BATTLE trial: personalizing therapy for lung cancer. Cancer Discov 1(1):44-53, 2011. e-Pub 2011. PMID: 22586319.
89. Yuan Y, Huang X, Liu S. A Bayesian response-adaptive covariate-balanced randomization design with application to a leukemia clinical trial. Stat Med 30(11):1218-29, 2011. e-Pub 2011. PMID: 21432894.
90. Savar A, Esmaeli B, Ho H, Liu S, Prieto VG. Conjunctival melanoma: local-regional control rates, and impact of high-risk histopathologic features. J Cutan Pathol 38(1):18-24, 2011. e-Pub 2011. PMID: 20860727.
91. Lee JJ, Gu X, Liu S. Bayesian adaptive randomization designs for targeted agent development. Clin Trials 7(5):584-96, 2010. e-Pub 2010. PMID: 20571130.
92. Wheler J, Tsimberidou AM, Moulder S, Cristofanilli M, Hong D, Naing A, Pathak R, Liu S, Feng L, Kurzrock R. Clinical outcomes of patients with breast cancer in a phase I clinic: the M. D. Anderson cancer center experience. Clin Breast Cancer 10(1):46-51, 2010. e-Pub 2010. PMID: 20133258.
93. Raso MG, Behrens C, Herynk MH, Liu S, Prudkin L, Ozburn NC, Woods DM, Tang X, Mehran RJ, Moran C, Lee JJ, Wistuba II. Immunohistochemical expression of estrogen and progesterone receptors identifies a subset of NSCLCs and correlates with EGFR mutation. Clin Cancer Res 15(17):5359-68, 2009. e-Pub 2009. PMID: 19706809.
94. Lambert LA, Armstrong TS, Lee JJ, Liu S, Katz MH, Eng C, Wolff RA, Tortorice ML, Tansey P, Gonzalez-Moreno S, Lambert DH, Mansfield PF. Incidence, risk factors, and impact of severe neutropenia after hyperthermic intraperitoneal mitomycin C. Ann Surg Oncol 16(8):2181-7, 2009. e-Pub 2009. PMID: 19475451.
95. Wheler J, Tsimberidou AM, Hong D, Naing A, Jackson T, Liu S, Feng L, Kurzrock R. Survival of patients in a Phase 1 Clinic: the M. D. Anderson Cancer Center experience. Cancer 115(5):1091-9, 2009. e-Pub 2009. PMID: 19165805.
96. William WN, Lee JL, Shin DM, Hong WK, Liu S, Lee JJ, Lippman SM, Khuri FR, Kim ES. Phase I trial of weekly topotecan and gemcitabine in patients with solid tumors. Am J Clin Oncol 32(1):15-9, 2009. e-Pub 2009. PMID: 19194117.
97. Ross WA, Ghosh S, Dekovich AA, Liu S, Ayers GD, Cleary KR, Lee JH, Couriel D. Endoscopic biopsy diagnosis of acute gastrointestinal graft-versus-host disease: rectosigmoid biopsies are more sensitive than upper gastrointestinal biopsies. Am J Gastroenterol 103(4):982-9, 2008. e-Pub 2008. PMID: 18028511.
98. Zhou X, Liu S, Kim ES, Herbst RS, Lee JJ. Bayesian adaptive design for targeted therapy development in lung cancer--a step toward personalized medicine. Clin Trials 5(3):181-93, 2008. e-Pub 2008. PMID: 18559407.
99. Tsao AS, He D, Saigal B, Liu S, Lee JJ, Bakkannagari S, Ordonez NG, Hong WK, Wistuba I, Johnson FM. Inhibition of c-Src expression and activation in malignant pleural mesothelioma tissues leads to apoptosis, cell cycle arrest, and decreased migration and invasion. Mol Cancer Ther 6(7):1962-72, 2007. e-Pub 2007. PMID: 17620427.
100. Raffel DM, Koeppe RA, Little R, Wang CN, Liu S, Junck L, Heumann M, Gilman S. PET measurement of cardiac and nigrostriatal denervation in Parkinsonian syndromes. J Nucl Med 47(11):1769-77, 2006. e-Pub 2006. PMID: 17079809.
101. Consens FB, Chervin RD, Koeppe RA, Little R, Liu S, Junck L, Angell K, Heumann M, Gilman S. Validation of a polysomnographic score for REM sleep behavior disorder. Sleep 28(8):993-7, 2005. e-Pub 2005. PMID: 16218083.
102. Koeppe RA, Gilman S, Joshi A, Liu S, Little R, Junck L, Heumann M, Frey KA, Albin RL. 11C-DTBZ and 18F-FDG PET measures in differentiating dementias. J Nucl Med 46(6):936-44, 2005. e-Pub 2005. PMID: 15937303.
103. Qin L, Moreno Rueda LY, Ray U, Mahmud I, Tan L, Lorenzi PL, Liu S, Lin HY, Mery DE, Zhan F, Shaughnessy JD, Yi Q, Acevedo Calado MJ, Wang H, Manasanch EE, Lee HC, Patel KK, Kuiatse I, Symer DE, Orlowski RZ. Targeting Caseinolytic Mitochondrial Matrix Peptidase, a Novel Contributor to High-risk Behavior, in Multiple Myeloma. Blood.

Review Articles

1. Smith LM, Mahoney DW, Bamlet WR, Yu F, Liu S, Goggins MG, Darabi S, Majumder S, Wang QL, Cote GA, Demeure MJ, Zhang Z, Srivastava S, Chawla A, Izmirlian G, Olson JE, Wolpin BM, Genkinger JM, Zaret KS, Brand R, Koay EJ, Oberg AL. Early detection of pancreatic cancer: Study design and analytical considerations in biomarker discovery and early phase validation studies. Pancreatology 24(8):1265-1279, 2024. e-Pub 2024. PMID: 39516175.
2. Liu S, Lee JJ. An Overview of the Design and Conduct of the BATTLE Trials. Chin Clin Oncol 4(3):33, 2015. e-Pub 2015. PMID: 26408300.

Other Articles

1. Liu, S, Yuan, Y Erratum to. Journal of the Royal Statistical Society. Series C: Applied Statistics 71(2):491-492, 2022.